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Background and Aim: Endoglin is a proliferation-associated antigen on endothelial cells and essential for angiogenesis. Soluble 
endoglin (s-endoglin), formed by proteolytic cleavage of ectodomain of membrane receptor could be an indicator of tumor-activat-
ed endothelium. The aim of present study was to analyze changes of s-endoglin level in plasma of lung cancer patients following 
surgical resection and to estimate the correlation of s-endoglin with other soluble receptors, sTie2 and sVEGF R1. Patients and 
Methods: The study group consisted of 37 patients with stage I of non-small cell lung cancer. Plasma concentrations of s-endoglin, 
sTie2 and sVEGF R1 were evaluated by ELISA, three times: before surgical resection and on postoperative day 7 and 30. Results: 
The median of s-endoglin concentration decreased significantly on postoperative day 7 when compared with preoperative level and 
next increased on 30th day and it was comparable with that before surgery. s-Endoglin correlated with another soluble receptors, 
with sTie2 both before surgery (r=0.44) and on postoperative day 7 (r=0.52) and on 30th day (r=0.58), with sVEGF R1 — only 
on postoperative day 7 (r=0.75). Conclusion: The increased level of serum endoglin in lung cancer patients compared to controls 
and its changes after surgical treatment suggest potential application of soluble form of endoglin as potential tumor marker.
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Endoglin �CD���� is a �8�-kDa cell membrane 
glycoprotein w�ic� serves as a coreceptor for trans-
forming growt� factor �TGF�-b� or TGF-b�� in t�e 
presence of t�e TGF-b type II receptor �TbRII� [�]. 
Endoglin is �ig�ly expressed by activated endot�elial 
cells �ECs� [�]. Hypoxia and TGF-b are two main factors 
t�at coope rate to induce its expression [�]. Endoglin 
promotes angiogenesis mainly by activation of vas-
cular ECs proliferation [�]. Endoglin overexpressed 
on endot�elia of vessels in several �uman solid ma-
lignancies [�] and its overexpression is associated 
wit� lower patient survival rates� presence of nodes 
metastases and distant metastatic disease [�].
Tumor vascular endot�elium s�ows up-regulation 
of various receptors� including t�e vascular endot�elial 
growt� factor receptor � �VEGF R�� and angiopoietin 
receptor� Tie� [7]. Two ot�er endot�elial receptors for 
angiogenic factors� t�e VEGF receptor � �VEGF R�� 
and t�e orp�an receptor Tie �� are also up regulated 
by �ypoxia [7]. So far� two different mec�anisms are 
known w�ic� lead to t�e formation of soluble receptors 
[8]. Firstly� soluble receptors can be translated from 
differentially spliced pre-mRNA molecules lacking t�e 
transmembrane domain �e. g.� sVEGF R�� [9] and t�e 
second mec�anism involves limited proteolysis in t�e 
extracellular domain of t�e membrane receptor leaving 
t�e ligand-binding domain intact �e. g.� sTie�� [8]. T�e 
external domain can be cleaved or s�ed and released 
into t�e circulation [7].
Similarly to classical receptors� accessory recep-
tor — endoglin exists in two forms: as a membrane-
bound and a soluble �s-endoglin� in t�e circulation. 
Recent findings [��] suggest t�at t�e ectodomain of en-
doglin is released t�roug� proteolytic cleavage by mem-
brane-type � matrix metalloproteinase ��T�-��P� — 
matrix metalloproteinase-�� ���P-���. Coexpression 
of endoglin wit� ��P-�� on t�e cell membrane leads 
to t�e cleavage of endoglin at t�e glycine-leucine 
bond at position �8�� releasing t�e nearly complete 
endoglin extracellular domain [��]. Hawinkels` et al. 
[��] study also s�ows t�at ��P-�� is t�e most abun-
dantly expressed �T-��P in ECs and t�at knock-
down of ��P-�� strongly reduces s-endoglin levels 
in t�e conditioned media of t�ese cells cultures. Local 
up-regulation of endot�elial ��P-�� expression may 
increase s-endoglin� decrease membrane-localized 
endoglin� and transform t�e endot�elium to a quiescent 
state [��]. Similarly to endoglin� ��P-�� is �ig�ly ex-
pressed not only by ECs� but also by several ot�er cell 
types� i. e. by cells of lung tumor [��]. In Atkinson’s et al. 
[��] studies� among all �T-��Ps ���Ps ��-�7� �� and 
���� ��P-��� -�� and ��7 displayed �ig�er expression 
in tumor relative to normal lung specimens. In addi-
tion ��P-�� mRNA expression strongly correlated 
to ��P-�� proteolytic activity in tumor models. T�ere-
fore� s-endoglin mig�t be s�ed not only from endot�elial 
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cells� but also from tumor cells. To conclude� t�e level 
of s-endoglin could be an indicator of tumor-activated 
endot�elium� but it depends on s�edding proteases 
expression� mainly ��P-��.
T�e soluble receptor displays biological activity 
by acting as a specific endogenous antagonist com-
plexing t�e corresponding ligand and t�us preventing 
t�e ligand-mediated signal transduction [8]; soluble 
receptors are capable of scavenging circulating 
ligands� e. g. VEGF can be bound to sVEGF R� [9]� 
Ang� and Ang� — to sTie� [8]. T�e role of s-endoglin 
is not yet clear� maybe it competes wit� TGF-b for 
TbRII binding [��]. But it is known t�at s-endoglin �as 
antiangiogenic properties; it is capable of reducing 
spontaneous and VEGF-induced angiogenesis. Also� 
s-endoglin fused wit� t�e Fc fragment of �uman im-
munoglobulin G strongly reduces microvessel density 
in a mouse model of invasive ductal breast carcinoma 
[��]. Experiment of Le et al. [��] s�owed two diffe-
rent oligomeric forms of recombinant s-endoglin. 
T�e dimeric s-endoglin en�anced TGF-b signalling 
in U9�7 cells� in a dose-dependent fas�ion. However� 
tetrameric s-endoglin was not active in t�is system� 
t�us� its biological relevance is not yet clear. T�is form 
of s-endoglin mig�t be a resting inactive form t�at can 
undergo conformational c�anges into dimeric or ot�er 
active forms under certain activating conditions. T�ey 
concluded t�at t�e recombinant s-endoglin is capable 
of modulating TGF-b signal effectively� t�us� can po-
tentially be applied for t�erapeutic purposes.
T�e quantification of soluble forms of receptors 
mig�t be interesting in terms of diagnostic and/
or prognostic� but also t�erapeutic applications. T�e 
aim of present study was to analyze t�e c�anges 
of s-endoglin level in plasma of lung cancer patients 
and to estimate t�e correlation of s-endoglin wit� ot�er 
soluble receptors� sTie� and sVEGF R�.
MATERIALS AND METHODS
Study population. T�e study included patients 
wit� stage I non-small cell lung cancer� w�o underwent 
tumor resection wit�out any preoperative t�erapy. 
T�ese patients were treated in t�e University Hospital 
Department of T�oracic Surgery and Tumors� Col-
legium �edicum in Bydgoszcz� Nicolaus Copernicus 
University in Toruń� during t�e years ���8�����. T�ree 
blood samples were taken from eac� patient: one prior 
to surgery and ot�ers on postoperative days 7 and ��.
T�e study protocol was approved by t�e Et�ical 
Committee of t�e Collegium �edicum in Bydgoszcz� 
Nicolaus Copernicus University in Toruń �Poland�. All 
patients gave consent.
Blood sampling and processing. s-Endoglin� 
sTie�� sVEGF R� concentrations were evaluated 
in plasma. Two millilitres of blood were taken from el-
bow vein. EDTA was used as an anticoagulant. Wit�in 
�� min after t�e collection� t�e blood samples were 
centrifuged at ��8°C for �� min at ���� x g. T�e plasma 
was stored at -7�°C.
s‑Endoglin determination. s-Endoglin� sTie�� 
sVEGF R� concentrations were assayed by commercial-
ly available sandwic� enzyme-linked immunosorbent 
assay kits from R&D Systems �Quantikine Human Endo-
glin/CD���� sTie�� sVEGF R� Immunoassay� R&D Sys-
tems Inc.� �inneapolis� USA�. Kit is designed to mea-
sure �uman endoglin/CD���� sTie�� sVEGF R� in cell 
culture supernates� serum� and plasma.
Statistical analysis was done using Wilcoxon 
signed-rank test and Pearson`s linear correlation. T�e re-
sults were considered statistically significant for p < �.��.
RESULTS
In Table � t�e comparison of s-endoglin concentra-
tion before surgical treatment of lung cancer patients 
and on 7t� day and ��t� day after tumor resection 
is presented. T�e median of s-endoglin concentration 
decreased on 7t� day w�en compared wit� preopera-
tive level �����.� vs. ����.� pg/ml; p < �.����� and 
t�en it increased on ��t� day to reac� greater values 
t�an on 7t� day ����7.� vs. ����.� pg/ml; p < �.���� but 
it was comparable wit� pretreatment level ����7.� vs. 
����.� pg/ml; p = �.�78�.
Table 1. The plasma concentration of s-endoglin in lung cancer patients 
before and after surgical treatment (median, range)
Time of determination
pBefore surgery On 7
th day after 
surgery
On 30th day after 
surgery
s-Endog-
lin [pg/ml]
4112.0
2740.0–6576.0
3212.0
2166.0–4077.0
4447.0
3339.0–5665.0
* <0.0001
** <0.001
Notes: * — Before vs. After 7; ** — After 7 vs. After 30
In t�is study t�e estimation of correlation between 
s-endoglin and ot�er soluble receptors was accom-
plis�ed �Table ��. T�e correlation between s-endoglin 
and sTie�� bot� before surgery �r=�.��� and on post-
operative day 7 �r=�.��� and on ��t� day �r=�.�8� 
was �ig�. However� s-endoglin was correlated wit� 
sVEGF R� only on postoperative day 7� t�is correlation 
was very �ig� �r=�.7��.
Table 2. The correlation between soluble receptors levels before and after 
surgery (p < 0.05 for all correlations)
sTie2 sVEGF R1
Before 
sur-
gery
On 7th   
day after 
surgery
On 30th   
day after 
surgery
Before 
surgery
On 7th   
day after 
surgery
On 30th   
day after 
surgery
s-Endo-
glin
Before r=0.44 r=-0.04
After 7 r=0.52 r=0.75
After 30 r=0.58 r=0.17
DISCUSSION
Endoglin is primarily expressed in proliferating 
vascular endot�elial cells� and its expression increases 
during tumor angiogenesis. Suc� properties �ave 
made endoglin a reliable marker of various solid tu-
mors vasculature [�����].
Soluble endoglin in serum is also elevated in vari-
ous cancers� including breast� colorectal and liver can-
cers� and it correlates wit� t�e presence of metastatic 
disease [�����].
Serum s-endoglin �as also prognostic value. 
It is an indicator of prostate cancer metastasis to t�e 
pelvic lymp� nodes and of bioc�emical recurrence 
after medical prostatectomy. In multivariate analysis� 
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only endoglin and Gleason score� but not PSA or clini-
cal stage� were predictive of lymp� node metastases 
[����8]. Elevated pretreatment plasma s-endoglin 
level is predictive for decreased clinical benefit and 
a s�orter overall survival in metastatic breast cancer 
patients treated wit� �nd-line �ormone t�erapy [�9].
Besides t�at� t�e �ig� level of s-endoglin de-
creased in patients receiving c�emot�erapy. Conven-
tional c�emot�erapy regimens suppress endot�elial 
cells in tumor vasculature and consequently in�ibit 
t�e release of s-endoglin from endot�elial cells [��].
In our study� after surgical resection of lung cancer 
t�e level of plasma s-endoglin decreased on 7th day w�en 
compared wit� preoperative level� and next on ��th day — 
increased and it was comparable wit� t�at before surgery 
intervention. T�is problem can be explained in t�e follo-
wing way. T�e decrease of s-endoglin probably is a conse-
quence of resection of tumor mass� �ig�ly vasculated and 
expressing bot� endoglin and s�edding enzyme� ��P-��. 
However� increase of s-endoglin on ��t� day in comparison 
wit� postoperative day 7 mig�t be t�e result of stimulation 
of ECs and circulating progenitor endot�elial cells �EPCs� 
by various tumor-derived angiogenic factors �e.g.� VEGF� 
Ang��� w�ic� levels in circulation after surgical treatment 
are increased [��� unpublis�ed own data].
�yśliwiec et al. [��] received similar results: after 
surgical treatment of colorectal cancer s-endoglin level 
on postoperative day � decreased w�en compared wit� 
preoperative level� t�en it increased on day �� to reac� 
greater values t�an on postoperative day �� but lower 
t�an preoperative point. T�ey explain t�ese c�anges 
as follows: decrease of s-endoglin level after surgery 
mig�t be at least in part due to t�e action of pro-inflam-
matory cytokines� suc� as tumor necrosis factor alp�a 
�TNF-alp�a�. TNF-alp�a �as been reported to down-
regulate endoglin at post-transcriptional level [��].
In our study t�ere were interesting correlations be-
tween plasma s-endoglin levels wit� ot�er soluble form 
of receptors. s-Endoglin correlated wit� sTie� bot� be-
fore and after surgery �BEFORE: r=�.��� AFTER �day 7�: 
r=�.��� AFTER �day ���: r=�.�8� and wit� sVEGF R� — 
only on postoperative day 7 �r=�.7��. T�ese two soluble 
receptors are formed in different manner: sTie�� simi-
larly to s-endoglin is produced by proteolytic proces-
sing� �owever� sVEGF R� derived predominantly from 
alternative splicing. T�is could explain above correla-
tions of s-endoglin: wit� sTie� — constant� and wit� 
sVEGF R� — only in one investigated point.
T�e increased level of serum endoglin in various 
cancers compared to controls� prognostic value of t�is 
angiogenic factor and c�anges of its level after c�e-
mot�erapy or surgical treatment suggest potential ap-
plication of soluble form of endoglin as tumor marker 
in t�e future.
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